Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Karyopharm Therapeutics
China Pharma Eyes Brighter SE Asia Markets Amid US Entry Shadows
Junshi is the latest Chinese company to announce plans to expand into Southeast Asia, where its compatriot firms are also eyeing large market potential and are set to benefit from less stringent reviews of China-only clinical data due to fewer questions around ethnic differences versus the US.
Multiple GPRC5D Agents For Myeloma Raise Questions On Positioning
J&J’s talquetamab is in the lead among bispecific antibodies, while Roche and BMS are not far behind. Presentations at ASH sparked discussion on how to position them in treatment.
Finance Watch: No New IPOs, But Two Firms Take The SPAC Route
Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.
The Real World Is Not Enough: Comparability Is Common Obstacle For RWE In US FDA Decisions
Unsuccessful attempts to use real-world evidence for approvals highlight the need to demonstrate relationship between real-world data and clinical trial patients. The Pink Sheet examines what went wrong for Bluebird/Bristol’s Abecma, Ultragenyx’s Dojolvi, and Karyopharm’s Xpovio.
- Other Names / Subsidiaries
- NPM Pharma, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.